OraSure Technologies Inc (OSUR) Stock
Key stats
- Market cap
- $245.81M
- Price / Earnings ratio
- -4.7x
- EPS (TTM)
- -$0.69
- Volume
- Loading
- 52-week high
- $4.58
- 52-week low
- $2.08
Source: third-party data provider, as of November 13, 2026
Compare with OSUR
Recent news

OraSure Technologies Q2 Earnings Call Highlights
OraSure Technologies Q2 Earnings Call Highlights
OSUR

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
OSUR

Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says
Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says
OSUR

Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
OSUR
Technical indicators
- RSI 14
- 45.94
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.04
- MACD histogram
- -0.05
- SMA 50
- $3.72
- Price below SMA 50
- EMA 50
- $3.75
- Price below EMA 50
- SMA 200
- $3.55
- Price above SMA 200
- EMA 200
- $3.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.22 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

OraSure Technologies Q2 Earnings Call Highlights
OraSure Technologies Q2 Earnings Call Highlights
OSUR

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
OSUR

Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says
Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says
OSUR

Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
OSUR

OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
OSUR

Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
OSUR

New Strong Buy Stocks for January 27th
New Strong Buy Stocks for January 27th
OSUR

3 Strong Buy Stocks Under $10: January 2024
3 Strong Buy Stocks Under $10: January 2024
OSUR

Buy These 4 Low-Beta Stocks to Counter Market Volatility
Buy These 4 Low-Beta Stocks to Counter Market Volatility
OSUR

7 Healthcare Stocks That Are Poised to Become the Next Unicorns
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
OSUR
About OraSure Technologies Inc
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Carrie Eglinton Manner | President, CEO & Director | 1975 |
| Mr. Kenneth J. McGrath | Chief Financial Officer | 1972 |
| Ms. Michele Anthony | Senior VP, Chief Accounting Officer, Controller & Assistant Secretary | 1974 |
| Ms. Karen Davies | Diagnostics R&D & Chief Technologist | — |
| Mr. Rafal Iwasiow Ph.D. | Sample Management Solutions R&D & Chief Scientist | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 45.94
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.04
- MACD histogram
- -0.05
- SMA 50
- $3.72
- Price below SMA 50
- EMA 50
- $3.75
- Price below EMA 50
- SMA 200
- $3.55
- Price above SMA 200
- EMA 200
- $3.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.0 | -3.3 | ||||||||||
| 2022 | +2.2 | -13.1 | -11.9 | -10.1 | -34.3 | -32.3 | +12.5 | +35.9 | -4.8 | +8.5 | +13.0 | -5.9 |
| 2023 | +16.5 | +18.2 | -1.6 | +10.9 | -27.9 | -9.4 | -6.7 | +39.2 | -7.9 | -12.7 | +40.2 | +14.5 |
| 2024 | -11.0 | -3.9 | -15.4 | -13.0 | -11.3 | -9.6 | +4.9 | -0.7 | -2.3 | -2.4 | -8.9 | -7.4 |
| 2025 | +13.6 | -11.0 | -5.6 | -9.9 | -2.0 | +5.3 | +5.6 | +10.0 | -4.5 | -13.0 | -10.9 | +0.4 |
| 2026 | +17.2 | +7.9 | +1.4 | -0.3 | +45.8 | +9.0 | -6.3 | -13.7 | +11.0 | +1.5 | -3.8 |



